All Oncology News

An sBLA seeking the approval of zenocutuzumab has been submitted to the FDA, and the agent was added to the NCCN guidelines for NRG1-positive cholangiocarcinoma.

Christian Capitini has been named the next director of the University of Wisconsin Carbone Cancer Center.

During a recent Peer Exchange, breast and lung cancer experts discussed comprehensive strategies for identifying and mitigating the AEs associated with ADCs.

Aaron Gerds, MD, details the rationale behind investigating agents targeting CALR mutations and other novel therapies in myeloproliferative neoplasms.

Alicia Morgans, MD, MPH, and Michael Schweizer, MD, discuss the phase 3 MEVPRO-1 and MEVPRO-2 trials of mevrometostat plus enzalutamide in mCRPC.

Mayo Clinic researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors.

The NCCN updated its 2026 Guidelines for breast cancer screening and diagnosis to include an AI-based risk assessment tool to predict breast cancer risk.

Metronomic treatment approaches could represent therapeutic avenues for patients with TP53-mutated myeloid malignancies.

The CSF-1R–targeting monoclonal antibody emactuzumab met key end points in the phase 3 TANGENT study, setting the stage for a BLA submission.

The allogeneic CAR T-cell therapy cema-cel improved MRD negativity rates vs observation as first-line consolidation in LBCL.

Frontline darovasertib plus crizotinib generated a PFS improvement vs treatment of investigator’s choice in HLA-A*02:01–negative metastatic uveal melanoma.

Sac-TMT plus pembrolizumab was safe and effective in recurrent/metastatic cervical cancer.

Tisotumab vedotin plus carboplatin & pembrolizumab ± bevacizumab achieved 65.8% ORR and 28-month median OS in first-line recurrent/metastatic cervical cancer.

Mirvetuximab soravtansine plus carboplatin showed antitumor activity and a manageable safety profile in patients with recurrent platinum-sensitive ovarian cancer.

Significantly improved response rates were shown for liso-cel vs real-world data for SOC in later-line relapsed or refractory mantle cell lymphoma.

ECOG PS should be evaluated before initiating this agent, as patients with poorer PS may experience shorter life expectancy than reported in trials.

Treatment with daraxonrasib led to PFS and OS benefits vs SOC cytotoxic chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma.

The FDA has accepted and granted priority review to the BLA seeking the approval of I-DXd in ES-SCLC.

Roswell Park Comprehensive Cancer Center researchers are investigating whether CAR T-cell therapy could target some of the most common autoimmune diseases.

Pirtobrutinib plus venetoclax and rituximab improved PFS in relapsed/refractory CLL/SLL, meeting the primary end point of BRUIN CLL-322.

Sofetabart mipitecan elicited strong antitumor activity in recurrent platinum-resistant high-grade serous ovarian cancer.

Ibrutinib given prior to apheresis was associated with improved outcomes with tisagenlecleucel vs postapheresis administration in relapsed/refractory LBCL.

R. Lor Randall, MD, FACS, highlights a recent meta-analysis comparing 2 approaches to surgical management for patients with femoral metastases.

The novel ADC DB-1311/BNT324 was effective in cervical cancer and PROC, regardless of prior treatment or histology

The B7-H3–targeting ADC demonstrated encouraging responses across multiple gynecologic cancers in a phase 1/2 trial.

Single-agent rezatapopt showed efficacy and safety irrespective of patients' platinum status, prior bevacizumab or PARP inhibitor exposure, or FRα expression.

The B7-H4–targeted ADC produced ORRs of 62% and 67% in patients with PROC and endometrial cancer, respectively, in the phase 1 BEHOLD-1 study.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, chronic lymphocytic leukemia, salivary gland cancer, cholangiocarcinoma, and prostate cancer.

Cadonilimab combined with chemotherapy demonstrated robust efficacy and a favorable safety profile in advanced or recurrent endometrial cancer.

Patients who received first-line niraparib as maintenance therapy had high resolution rates and low number of discontinuations due to hematologic PSEOIs.